...
首页> 外文期刊>Molecular pharmacology. >Negative Gating Modulation by (R)-N-(Benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphthylamine (NS8593) Depends on Residues in the Inner Pore Vestibule: Pharmacological Evidence of Deep-Pore Gating of KCa2 Channels.
【24h】

Negative Gating Modulation by (R)-N-(Benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphthylamine (NS8593) Depends on Residues in the Inner Pore Vestibule: Pharmacological Evidence of Deep-Pore Gating of KCa2 Channels.

机译:(R)-N-(苯并咪唑-2-基)-1,2,3,4-四氢-1-萘胺(NS8593)的负门控调制取决于内部孔前庭中的残留:深孔门控的药理学证据KCa2通道数。

获取原文
获取原文并翻译 | 示例
           

摘要

Acting as a negative gating modulator, (R)-N-(benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphthylamine (NS8593) shifts the apparent Ca(2+)-dependence of the small-conductance Ca(2+)-activated K(+) channels K(Ca)2.1-2.3 to higher Ca(2+) concentrations. Similar to the positive K(Ca) channel-gating modulators 1-ethyl-2-benzimidazolinone (1-EBIO) and cyclohexyl-[2-(3,5-dimethyl-pyrazol-1-yl)-6-methylpyrimidin-4-yl]-amine (CyPPA), the binding site for NS8593 has been assumed to be located in the C-terminal region, in which these channels interact with their Ca(2+) sensor calmodulin. However, by using a progressive chimeric approach, we were able to localize the site-of-action of NS8593 to the K(Ca)2 pore. For example, when we transferred the C terminus from the NS8593-insensitive intermediate-conductance K(Ca)3.1 channel to K(Ca)2.3, the chimeric channel remained as sensitive to NS8593 as wild-type K(Ca)2.3. In contrast, when we transferred the K(Ca)2.3 pore to K(Ca)3.1, the channel became sensitive to NS8593. Using site-directed mutagenesis, we subsequently identified two specific residues in the inner vestibule of K(Ca)2.3 (Ser507 and Ala532) that determined the effect of NS8593. Mutation of these residues to the corresponding residues in K(Ca)3.1 (Thr250 and Val275) made K(Ca)2.3 insensitive to NS8593, whereas introduction of serine and alanine into K(Ca)3.1 was sufficient to render this channel highly sensitive to NS8593. It is noteworthy that the same two residue positions have been found previously to mediate sensitivity of K(Ca)3.1 to clotrimazole and 1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole (TRAM-34). The location of Ser507 in the pore-loop near the selectivity filter and Ala532 in an adjacent position in S6 are within the region predicted to contain the K(Ca)2 channel gate. Hence, we propose that NS8593-mediated gating modulation occurs via interaction with gating structures at a position deep within the inner pore vestibule.
机译:充当负门控调节剂,(R)-N-(苯并咪唑-2-基)-1,2,3,4-四氢-1-萘胺(NS8593)转移了小分子的明显Ca(2+)依赖性Ca(2+)激活的K(+)通道将K(Ca)2.1-2.3传递给更高的Ca(2+)浓度。类似于正K(Ca)通道门控调节剂1-乙基-2-苯并咪唑啉酮(1-EBIO)和环己基-[2-(3,5-二甲基-吡唑-1-基)-6-甲基嘧啶-4- yl]-胺(CyPPA),NS8593的结合位点被假定位于C端区域,在这些区域中这些通道与其Ca(2+)传感器钙调蛋白相互作用。但是,通过使用渐进式嵌合方法,我们能够将NS8593的作用位点定位在K(Ca)2孔中。例如,当我们将C末端从对NS8593不敏感的中等电导K(Ca)3.1通道转移到K(Ca)2.3时,嵌合通道对NS8593的敏感性仍然与野生型K(Ca)2.3相同。相反,当我们将K(Ca)2.3孔转移到K(Ca)3.1时,通道对NS8593变得敏感。使用定点诱变,我们随后在K(Ca)2.3的内部前庭中确定了两个特定的残基(Ser507和Ala532),这些残基决定了NS8593的作用。这些残基突变为K(Ca)3.1(Thr250和Val275)中的相应残基使得K(Ca)2.3对NS8593不敏感,而向K(Ca)3.1中引入丝氨酸和丙氨酸足以使该通道对K(Ca)3.1高度敏感NS8593。值得注意的是,先前已经发现了相同的两个残基位置来介导K(Ca)3.1对克霉唑和1-[((2-氯苯基)二苯甲基] -1H-吡唑(TRAM-34)的敏感性。 Ser507在选择性过滤器附近的孔环中的位置以及Ala532在S6中的相邻位置中的位置在预计包含K(Ca)2通道门的区域内。因此,我们提出NS8593介导的门控调节是通过与内孔前庭深处的门控结构相互作用而发生的。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号